HC Wainwright Increases Earnings Estimates for Celcuity

Celcuity, Inc. (NASDAQ:CELC) – Equities research analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of Celcuity in a research note issued on Friday, March 27th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.81 per share for the year, up from their previous estimate of $0.65. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity’s FY2029 earnings at $7.97 EPS.

A number of other research firms have also recently issued reports on CELC. Wall Street Zen upgraded shares of Celcuity from a “sell” rating to a “hold” rating in a research note on Saturday. Wells Fargo & Company initiated coverage on Celcuity in a report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Stifel Nicolaus boosted their price objective on Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Needham & Company LLC restated a “buy” rating and set a $122.00 target price on shares of Celcuity in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Price Performance

Shares of Celcuity stock opened at $106.02 on Monday. The stock has a market capitalization of $5.13 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38. The firm’s 50-day moving average price is $109.49 and its two-hundred day moving average price is $91.20. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. Celcuity has a 1-year low of $7.57 and a 1-year high of $120.32.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.09.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director directly owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 15.78% of the company’s stock.

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently modified their holdings of the business. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Celcuity during the third quarter worth approximately $27,000. EverSource Wealth Advisors LLC boosted its stake in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE boosted its stake in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the period. Finally, Meeder Asset Management Inc. acquired a new stake in Celcuity during the 4th quarter worth $42,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.